CervoMed Inc. (CRVO)

Market Cap	73.97M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
Shares Out	8.70M
EPS (ttm)	-2.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,596,322
Open	7.72
Previous Close	7.71
Day's Range	7.33 - 10.72
52-Week Range	1.80 - 25.92
Beta	n/a
Analysts	Strong Buy
Price Target	25.43 (+199.18%)
Earnings Date	Mar 17, 2025

About CRVO

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery. The company develops EIP200 for central nervous system which is in preclinical trials. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: CRVO
• Website: https://www.cervomed.com

Financial Performance

In 2024, CervoMed's revenue was $9.74 million, an increase of 36.29% compared to the previous year's $7.14 million. Losses were -$16.29 million, 650.1% more than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for CRVO stock is "Strong Buy." The 12-month stock price forecast is $25.43, which is an increase of 199.18% from the latest price.

Price Target

$25.43

(199.18% upside)

Analyst Consensus: Strong Buy